Sansimeon Inc

A Uniquely Scalable Approach to Single Cell Sequencing for the Development of Next Generation Cell Therapies - Immunotherapies (including Car-t Cell Therapies) Are Wonder Drugs When They Work, But the Response Rates of Today’s Immunotherapies Are Only 15-20% and Therapy Costs Remain Prohibitively High for Mass Adoption. Single-cell Sequencing (sc-seq) Is Becoming the Preferred Tool for Immune Profiling to Map a Patient’s Adaptive Immune Response, and to Readout Phenotypic Changes That Result From Crispr Based Gene Edits at the Single Cell Level. However, the Full Potential of Sc-seq Based Crispr Screens and Immune Repertoire Profiling for the Development of Next Generation Therapeutics Requires a 10-FOLD to 100-FOLD Increase in Cell Throughput Relative to Current Platforms. Upcoming Expiration of Illumina’s Core Ip Re-ignited Competition in Us & Eu Markets. the Resulting Re-acceleration in the Drop of Dna Sequencing Costs (6-FOLD Price Reduction in 2023 VS. Illumina’s 2022 Pricing) Makes Sc-seq of 10 Million Cells Affordable Today (20-30 Million Cells in ~3 Years and 100 Million Cells in 6 Years), But Existing Methods for Sc-seq Do Not Support Throughput Beyond 1 Million Cells Per Experiment. Proposed Alternatives Are Scalable, But Trade-offs in Performance and Ease-of-use Make Them Unsuitable for Translational Research. Sansimeon’s Approach Uniquely Scales Sc-seq With Throughput >100M Cells, While Retaining the Ease-of-use and Necessary Cell Capture Efficiency for High-throughput Applications in Translational Research. Our Platform Incorporates a Technology for In-line Sample Debulking, Which Was Previously Commercialized for Applications in Cell Therapy Manufacturing and Rare Cell Isolation. Sansimeon’s Ability to Sequence >100 Million Single Cells Directly From Crude & Complex Samples (such as Whole Blood or Bone Marrow Aspirates), With a Single-step Automated Workflow, Makes the Platform Ideally Suited for High-throughput Applications in Translational Research.